Dose finding study for the use of subcutaneous recombinant interleukin-2 to augment natural killer cell numbers in an outpatient setting for stage 4 neuroblastoma after megatherapy and autologous stem-cell reinfusion.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples